Skip to main content

Table 1 Ongoing clinical trials of new drugs against retinal and choroidal angiogenesis

From: Retinal and choroidal angiogenesis: a review of new targets

NCT number Drug Target/mechanism Phase Conditions
NCT02543229 OPT-302 VEGF-C VEGF-D 1 Eye diseases, macular degeneration, retinal diseases, retinal degeneration, pathologic neovascularization
NCT02591914 E10030 (Fovista) PDGF 1 Neovascular age-related macular degeneration
NCT01940887 3
NCT02348359 X-82 VEGF 2 Age-related macular degeneration, macular degeneration, exudative age-related macular degeneration, age-related macular degeneration, eye diseases, retinal degeneration, retinal diseases
PDGF
NCT02699450 RO6867461 VEGF 2 Diabetic macular edema
ANG-2
NCT02530918 DS-7080ª Robo-4 1 Neovascular age-related macular degeneration
NCT02727881 OHR-102 (Squalamine lactate) VEGF 3 Age-related macular degeneration
PDGF
bFGF
NCT02857517 Conbercept VEGF-A 2 Proliferative diabetic retinopathy, idiopathic choroidal neovascularization, retinal vein occlusion, polypoidal choroidal vasculopathy, branch retinal vein occlusion, macular edema, neovascular glaucoma, age-related macular degeneration, pathological myopia, diabetic macular edema, wet age-related macular degeneration
NCT02911311   VEGF-B NP  
NCT03108352   VEGF-C 3  
NCT03159884   PlGF 4  
NCT03154892    NP  
NCT03128463    NP  
NCT02194634    3  
NCT03054818    NP  
NCT01024998 AAV2-sFLT01 Vector to neutralizes VEGF 1 Macular degeneration, age-related maculopathies, age-related maculopathy, retinal degeneration, retinal neovascularization, gene therapy, eye diseases
NCT02307682 RTH258 (Brolucizumab) VEGF-A 3 Neovascular age-related macular degeneration
NCT02434328     
NCT02713204 REGN910 (Nesvacumab) Inactivates the Tie2 receptor ligand ANG-2 2 Neovascular age-related macular degeneration
NCT02555306 DE-122 Endoglin 2 Age-related macular degeneration
NCT02914639 SF0166 Topical Ophthalmic Solution Integrin αvβ3 2 Age-related macular degeneration
NCT02462928 Abicipar pegol VEGF 3 Macular degeneration
PDGF
NCT02867735 LKA651 Erythropoietin 1 Macular edema, diabetic macular edema, neovascular age-related macular degeneration, retinal vein occlusions
NCT02613559 TK001 (Sevacizumab) VEGF 1 Neovascular age-related macular degeneration
NCT02484690 RG7716 VEGF 2 Macular degeneration, choroidal neovascularization
ANG-2
NCT03066258 RGX-314 gene therapy VEGF 1 Neovascular age-related macular degeneration, wet age-related macular degeneration
  1. From http://www.clinicaltrials.gov. Accessed June 11, 2017. Searched terms: ocular angiogenesis, age-related macular degeneration, retinal neovascularization, choroidal neovascularization; Recruitment: “closed studies/active, not recruiting” AND “open studies/recruiting”. Abbreviations: ANG-2, angiopoietin-2; bFGF, Basic fibroblast growth factor; NCT, National Clinical Trial; PlGF, Placental growth factor; Robo-4, Roundabout Guidance Receptor-4; NP, not provided; VEGF, vascular endothelial growth factor